ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

CHOP Evaluation Plan In Jan. 22 Issue

January 15, 1982

SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.

April 30, 2004

Correction: Appropriations Reports Included Language of Minorities and Underserved

October 15, 1999

DCT Board Approves New RFA For Aids Clinical Trials Groups

November 11, 1994

UC Davis Study Finds Patients Need Practical Information

June 28, 2002

NCI Publishes Report On Pancreatic Cancer

March 7, 2014